In partnership with Screenin3D, we deliver advanced 3D cell platforms and 3D assays that revolutionize your research with cutting-edge, realistic cellular models.
As therapeutic strategies evolve, the need for more physiologically relevant assays is rapidly increasing. To meet this demand, RoukenBio has formed a strategic partnership with ScreenIn3D, combining RoukenBio’s expertise in immunology and high-content readouts with ScreenIn3D’s innovative 3D miniaturized microfluidic technology.
Together, we deliver advanced, physiologically relevant assays including 3D biological assay formats and complex immunology assays that accelerate your drug discovery process.
ScreenIn3D’s proprietary UpScale 3D lab-on-a-chip technology miniaturizes complex assays, offering 20X higher throughput than traditional systems and enabling highly efficient in vitro immunology assays.
Our deep knowledge of immunology allows us to design highly predictive assays using patient-derived biopsy material, closely mimicking human biological conditions and strengthening the impact of your immunology assays.
RoukenBio delivers precise, high-content data through sophisticated readouts and analytics, providing comprehensive insights into immune cell activity, signal transduction, and cellular interactions across both 2D and 3D assays.
With ScreenIn3D’s microfluidic platform and RoukenBio’s advanced analytical capabilities, we generate high-quality, actionable data in less time, streamlining your research process and enhancing the value of your in vitro immunology assays.
By utilizing patient biopsy material in co-culture systems, we create highly relevant, physiologically accurate models for more precise drug testing, supporting complex 3D biological assay development.
Our collaboration enables complex combination tests and modalities with unmatched scalability and precision, addressing a wide range of research needs across immunology assays and 3D platforms.
Together, we offer a range of validated protocols to create bespoke 3D complex in vitro models tailored to your specific therapeutic goals, including advanced 3D assays for immune–tumor and multi-cellular systems.
By combining ScreenIn3D’s pioneering technology with RoukenBio’s immunology expertise and high-content readouts, we deliver state-of-the-art 3D assay solutions that provide faster, more accurate, and highly predictive results bringing you closer to clinical success.
In partnership with Screenin3D, we deliver advanced 3D cell platforms that transform your research with cutting-edge, physiologically relevant miniaturized 3D cancer models.
As a global pharmaceutical contract research organization, RoukenBio provides drug development services to the vast scientific network worldwide. Our scientific partners are based mainly in the USA—particularly in Massachusetts (Boston, Cambridge) and California (San Francisco and San Diego)—Canada (from Vancouver up to Seattle), the UK, and Europe.
